Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
BiondVax Pharmaceuticals (BVXV)
NASDAQ:BVXV
BiondVax (BVXV) Stock Price & Analysis
273 Followers
BVXV Stock Chart & Stats
Day’s Range$1.32 - $1.37
52-Week Range― - ―
Previous Close$1.31
Volume23.02K
Average Volume (3M)N/A
Market Cap
$4.94M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
Nov 28, 2023EPS Estimate
-$0.94Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
BiondVax News
Ownership Overview
0.00%
Insiders
0.00% Mutual Funds
5.23% Other Institutional Investors
94.77% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
BVXV FAQ
What was BiondVax Pharmaceuticals’s price range in the past 12 months?
Currently, no data Available
What is BiondVax Pharmaceuticals’s market cap?
Currently, no data Available
When is BiondVax Pharmaceuticals’s upcoming earnings report date?
BiondVax Pharmaceuticals’s upcoming earnings report date is Nov 28, 2023 which is 143 days ago.
How were BiondVax Pharmaceuticals’s earnings last quarter?
BiondVax Pharmaceuticals released its earnings results on Aug 11, 2023. The company reported -$0.003 earnings per share for the quarter, beating the consensus estimate of -$0.455 by $0.452.
Is BiondVax Pharmaceuticals overvalued?
According to Wall Street analysts BiondVax Pharmaceuticals’s price is currently Overvalued.
Does BiondVax Pharmaceuticals pay dividends?
BiondVax Pharmaceuticals does not currently pay dividends.
What is BiondVax Pharmaceuticals’s EPS estimate?
BiondVax Pharmaceuticals’s EPS estimate is -$0.94.
How many shares outstanding does BiondVax Pharmaceuticals have?
Currently, no data Available
What happened to BiondVax Pharmaceuticals’s price movement after its last earnings report?
BiondVax Pharmaceuticals reported an EPS of -$0.003 in its last earnings report, beating expectations of -$0.455. Following the earnings report the stock price went down -1.515%.
Which hedge fund is a major shareholder of BiondVax Pharmaceuticals?
Among the largest hedge funds holding BiondVax Pharmaceuticals’s share is ARK Investment Management LLC. It holds BiondVax Pharmaceuticals’s shares valued at N/A.
---
BiondVax Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-87.52%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-22.20%
Trailing 12-Months
Company Description
BiondVax Pharmaceuticals
BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases. It works on M-001, a synthetic peptide-based protein targeting both seasonal and pandemic strains of the influenza virus. The company was founded by Ron Babecoff and Rami Epstein on July 22, 2003 and is headquartered in Jerusalem, Israel.
---
Technical Analysis
---